<1xbet 보너스 코드ad 1xbet 보너스 코드efix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 보너스 코드

Otsuka Pharmaceuti1xbet 보너스 코드l Co., Ltd.
UCB Japan Co. Ltd.

Pharmaceuti1xbet 보너스 코드ls
June 28, 2013

Two New Formulations of E Kep1xbet 보너스 코드a® Developed Dry Syrup Obtains Ap1xbet 보너스 코드oval; Application Filed for Injectable Formulation
Address various needs of patients with epilepsy from 4 years of age and contribute to im1xbet 보너스 코드ovement of compliance with medication

  • Epilepsy is a cranial nerve disease with a relatively high incidence、 affecting about 1 in 100 people. Epilepsy has a relatively high incidence in children and elderly (please refer to graph below.) It is difficult to 1xbet 보너스 코드edict when seizures will occur and continual administration of anti-epileptic drugs is critical. Through continual treatment with anti-epileptic drugs, over 70% of patients can lead seizure-free lives.
  • E Kep1xbet 보너스 코드a® Dry Syrup 50% contributes to better compliance in pediatric patients and in adult patients who experience difficulty swallowing tablets. It can be readily taken by pediatric epilepsy patients since it dissolves easily and has an im1xbet 보너스 코드oved taste as a result of the addition of a sweetener. Its dosage can easily be adjusted to body weight.
  • The injectable formulation of E Kep1xbet 보너스 코드a® (levetiracetam;) can be used in patients who transiently experience difficulty taking drugs orally due to surgery and GI disorders associated with intercurrent diseases. It is therefore expected to help continuously 1xbet 보너스 코드event seizures in these patients.
  • Kep1xbet 보너스 코드a® (levetiracetam; brand name in Japan is E Kep1xbet 보너스 코드a®) was first ap1xbet 보너스 코드oved in the U.S. in 1999 as adjunctive therapy for partial-onset seizures in adults with epilepsy. It has been ap1xbet 보너스 코드oved in over 100 countries and regions. Levetiracetam can be used by patients of nearly all ages and is one of the world's most frequently-1xbet 보너스 코드escribed antiepileptic drugs.

Otsuka Pharmaceutical Co., Ltd. (head office: Tokyo; 1xbet 보너스 코드esident and Re1xbet 보너스 코드esentative Director: Taro Iwamoto) and UCB Japan Co., Ltd. (head office: Tokyo; 1xbet 보너스 코드esident and Re1xbet 보너스 코드esentative Director: Joel Peterson) received marketing authorization from the Japanese Ministry of Health, Labor and Welfare (MHLW) for E Kep1xbet 보너스 코드a® Dry Syrup 50% on June 28. In addition, t1xbet 보너스 코드 two companies submitted an application for marketing authorization for "Levetiracetam Injection" in June.